HIPRA is an European multinational pharmaceutical company focused on prevention and diagnosis for animal and human health, with a broad range of highly innovative vaccines and an advanced diagnostic service. HIPRA has a solid international presence with 39 subsidiaries in different countries, 2 production plants and 11 diagnostic centres. Moreover, our extensive international distribution network keeps open channels of marketing with nearly 100 other countries, thereby covering the five continents. Research is a priority. HIPRA is the laboratory that has launched the most innovative vaccines and technology in the last ten years, with a total of 22 vaccines. The company allocates 10% of its annual revenue to R&D activities and 16% of its workforce is part of the R&D department. HIPRA lies in 6th place in the worldwide ranking of animal health vaccines.